Drug Profile
Research programme: eye disorder therapeutics - ImprimisRx
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Imprimis Pharmaceuticals
- Developer ImprimisRx
- Class Eye disorder therapies; Glucans; Glycerols; Glycosaminoglycans
- Mechanism of Action Cell membrane structure modulators; Free radical scavengers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Eye disorders
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Eye-disorders in USA (Ophthalmic)
- 31 Dec 2018 Imprimis Pharmaceuticals changed its name to Harrow Health and added all ophthalmology business to its subsidiary ImprimisRx
- 06 Apr 2017 Early research in Eye disorders in USA (Ophthalmic)